J&J expects weak sales of Procrit
WASHINGTON Johnson & Johnson is expecting continued weakness in the market this year for its erythropoiesis-stimulating agent Procrit despite gaining share in the retail and hospital settings, the company said.
Procrit is marketed by J&J in the U.S. for all uses outside dialysis and diagnostic applications under a license granted by Amgen.
Amgen manufactures two big anemia drugs, Aranesp and Epogen, which decreased in sales in the fourth quarter, combined by 28 percent. Aranesp decreased 25 percent to $827 million and Epogen decreased by 3 percent to $638 million.
The Centers for Medicare and Medicaid Services restricted reimbursement for the class of drugs last year over safety concerns with the products, a decision that was formally appealed by Amgen.
Boom in pharmacy openings leads to shortage of pharmacists
ALEXANDRIA, Va. and ST. LOUIS, Ill. Pharmacies are booming in business and as a result new stores are being built at a rapid pace, so much so that there aren’t enough pharmacists to fill the new job openings, according to published reports.
According to the National Association of Chain Drug Stores, there were 3,600 full-time openings for pharmacists throughout the nation last year reported by 37,000 member stores.
The reasons for the shortage, according to the National Community Pharmacists Association, are changes in insurance policies and federal regulations, which have made drugs more available to people. Also, the number of prescriptions being dispensed has grown from 2 billion to 3.2 billion in the last decade.
In Illinois, the state is trying to solve the shortage by opening more pharmacy schools. “I think a lot of new schools coming on board here will help alleviate the problem,” Phil Medon, dean of Southern Illinois University Edwardsville School of Pharmacy, said. “We haven’t had any graduates, yet, but long-term expansion at existing schools—plus new schools—are designed to help alleviate the shortage.”
MTBC receives Microsoft partner honor
SOMERSET, N.J. MTBC, an information technology company has received the distinguished Gold Certified Partner status in the Microsoft Partner Program. The company focuses on revenue cycle management and electronic medical record solutions.
As a Microsoft Gold Certified Partner, MTBC has demonstrated expertise with Microsoft technologies and platforms. MTBC’s IT staff has successfully completed a series of examinations demonstrating the company’s competency and aptitude in utilizing and delivering Microsoft’s advanced technologies. MTBC gains access to a rich set of tools designed to help its physician clients realize improved billing and practice management solutions.
“We are very pleased to have attained Microsoft Gold Certified Partner status,” said David Rosenblum, president of MTBC. “Our Microsoft gold certification further distinguishes us from our competition. It will assist us as continue to leverage technology and deliver Internet-based revenue cycle and practice management services that enable medical providers to streamline and increase collections, while reducing associated costs.”